

## SUNDAY, DECEMBER 2

---

Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone, and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma

**Shaji Kumar, M.D.**

Apixaban, Dalteparin in Active Cancer-Associated Venous Thromboembolism, the ADAM VTE Trial

**Robert McBane, M.D.**

### **Grand Ballroom 7**

Marriott Marquis San Diego Marina

8:15 a.m.

### **Room 33B**

San Diego Convention Center

4:30 p.m.

## MONDAY, DECEMBER 3

---

Mutation-Enhanced International Prognostic Systems for Essential Thrombocythemia (MIPSS-ET) and Polycythemia Vera (MIPSS-PV)

**Ayalew Tefferi, M.D.**

Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia

**Jonas Paludo, M.D.**

Changes in Imaging Surveillance of Diffuse Large B-Cell Lymphoma Survivors after Publication of the American Society of Hematology Choosing Wisely® Recommendations

**Urshila Durani, M.D.**

Patient-Reported Outcome-Driven Case Management System for Hematology—A Prospective Study

**Rahma Warsame, M.D.**

Mass Spectrometry to Measure Response in Immunoglobulin Light Chain Amyloidosis (AL)

**Angela Dispenzieri, M.D.**

Patterns of Care and Outcomes in Mantle Cell Lymphoma in the Modern Immunochemotherapy Era

**Alessia Castellino, M.D.**

### **Grand Hall D**

Manchester Grand Hyatt San Diego

7:15 a.m.

### **Room 24B**

San Diego Convention Center

7:45 a.m.

### **Room 11B**

San Diego Convention Center

8:15 a.m.

### **Room 25B**

San Diego Convention Center

11:30 a.m.

### **Hall GH**

San Diego Convention Center

6–8 p.m.

### **Hall GH**

San Diego Convention Center

6–8 p.m.